278 related articles for article (PubMed ID: 7543714)
1. Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide.
Bartoloni A; Norelli F; Ceccarini C; Rappuoli R; Costantino P
Vaccine; 1995 Apr; 13(5):463-70. PubMed ID: 7543714
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.
Devi SJ; Zollinger WD; Snoy PJ; Tai JY; Costantini P; Norelli F; Rappuoli R; Frasch CE
Infect Immun; 1997 Mar; 65(3):1045-52. PubMed ID: 9038314
[TBL] [Abstract][Full Text] [Related]
3. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine.
Jennings HJ; Roy R; Gamian A
J Immunol; 1986 Sep; 137(5):1708-13. PubMed ID: 3091688
[TBL] [Abstract][Full Text] [Related]
4. PEG as a spacer arm markedly increases the immunogenicity of meningococcal group Y polysaccharide conjugate vaccine.
Huang Q; Li D; Kang A; An W; Fan B; Ma X; Ma G; Su Z; Hu T
J Control Release; 2013 Nov; 172(1):382-389. PubMed ID: 23511718
[TBL] [Abstract][Full Text] [Related]
5. Bordetella pertussis fimbriae are effective carrier proteins in Neisseria meningitidis serogroup C conjugate vaccines.
Reddin KM; Crowley-Luke A; Clark SO; Vincent PJ; Gorringe AR; Hudson MJ; Robinson A
FEMS Immunol Med Microbiol; 2001 Aug; 31(2):153-62. PubMed ID: 11549423
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.
Jin Z; Chu C; Robbins JB; Schneerson R
Infect Immun; 2003 Sep; 71(9):5115-20. PubMed ID: 12933854
[TBL] [Abstract][Full Text] [Related]
7. Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.
Rubinstein LJ; García-Ojeda PA; Michon F; Jennings HJ; Stein KE
Infect Immun; 1998 Nov; 66(11):5450-6. PubMed ID: 9784556
[TBL] [Abstract][Full Text] [Related]
8. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
Jennings HJ
Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
[No Abstract] [Full Text] [Related]
9. N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis.
Pon RA; Lussier M; Yang QL; Jennings HJ
J Exp Med; 1997 Jun; 185(11):1929-38. PubMed ID: 9166422
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of two types of meningococcal group C polysaccharide conjugates using tetanus toxoid as carrier protein.
Beuvery EC; Roy R; Kanhai V; Jennings HJ
Dev Biol Stand; 1986; 65():197-204. PubMed ID: 3104115
[TBL] [Abstract][Full Text] [Related]
11. Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines.
Tontini M; Berti F; Romano MR; Proietti D; Zambonelli C; Bottomley MJ; De Gregorio E; Del Giudice G; Rappuoli R; Costantino P; ; Brogioni G; Balocchi C; Biancucci M; Malito E
Vaccine; 2013 Oct; 31(42):4827-33. PubMed ID: 23965218
[TBL] [Abstract][Full Text] [Related]
12. New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization.
Cuello M; Cabrera O; Martinez I; Del Campo JM; Camaraza MA; Sotolongo F; Pérez O; Sierra G
Vaccine; 2007 Feb; 25(10):1798-805. PubMed ID: 17240485
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults.
Richmond P; Goldblatt D; Fusco PC; Fusco JD; Heron I; Clark S; Borrow R; Michon F
Vaccine; 1999 Nov; 18(7-8):641-6. PubMed ID: 10547423
[TBL] [Abstract][Full Text] [Related]
14. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates.
Jennings HJ; Lugowski C
J Immunol; 1981 Sep; 127(3):1011-8. PubMed ID: 6790606
[TBL] [Abstract][Full Text] [Related]
15. Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group A polysaccharide conjugate vaccine.
Zhang T; Yu W; Wang Y; Hu T
Vaccine; 2015 Jun; 33(28):3208-14. PubMed ID: 25964170
[TBL] [Abstract][Full Text] [Related]
16. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial.
MacDonald NE; Halperin SA; Law BJ; Forrest B; Danzig LE; Granoff DM
JAMA; 1998 Nov; 280(19):1685-9. PubMed ID: 9832000
[TBL] [Abstract][Full Text] [Related]
17. Epitopes recognized by a nonautoreactive murine anti-N-propionyl meningococcal group B polysaccharide monoclonal antibody.
Moe GR; Dave A; Granoff DM
Infect Immun; 2005 Apr; 73(4):2123-8. PubMed ID: 15784554
[TBL] [Abstract][Full Text] [Related]
18. Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM
Beresford NJ; Martino A; Feavers IM; Corbel MJ; Bai X; Borrow R; Bolgiano B
Vaccine; 2017 Jun; 35(28):3598-3606. PubMed ID: 28408122
[TBL] [Abstract][Full Text] [Related]
19. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
[TBL] [Abstract][Full Text] [Related]
20. Immunological evaluation of meningococcal group C polysaccharide-tetanus toxoid conjugate in mice.
Beuvery EC; van Delft RW; Miedema F; Kanhai V; Nagel J
Infect Immun; 1983 Aug; 41(2):609-17. PubMed ID: 6409811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
